Gilead Sciences Inc   (GILD)
Other Ticker:  
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
Price: $66.5100 $0.87 1.325%
Day's High: $66.1716 Week Perf: 4.18 %
Day's Low: $ 65.55 30 Day Perf: 0.42 %
Volume (M): 553 52 Wk High: $ 80.92
Volume (M$): $ 36,495 52 Wk Avg: $66.48
Open: $65.74 52 Wk Low: $56.56

 Market Capitalization (Millions $) 84,202
 Shares Outstanding (Millions) 1,266
 Employees 11,800
 Revenues (TTM) (Millions $) 24,689
 Net Income (TTM) (Millions $) 89
 Cash Flow (TTM) (Millions $) -5,634
 Capital Exp. (TTM) (Millions $) 650

Gilead Sciences Inc
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. We have six products that are currently marketed in the U.S., all of which are also marketed in other countries worldwide. Our research and clinical programs are focused on anti-infectives, including antivirals and antifungals. We endeavor to grow our existing portfolio of products through proprietary clinical development programs, internal discovery programs and an active product acquisition and in-licensing strategy.

   Company Address: 333 Lakeside Drive Foster City 94404 CA
   Company Phone Number: 574-3000   Stock Exchange / Ticker: NASDAQ GILD
   GILD is expected to report next financial results on February 24, 2022.

Customers Net Income fell by GILD's customers Net margin fell to 20.81 %

-44.63 %

1.22 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV        3.47% 
PFE        2.94% 
ABT   -2.48%    
BMY   -2.04%    
MRK        0.77% 
JNJ        3.11% 
• View Complete Report

Ishares S and p Gsci Commodity indexed Trust

Ishares S And P Gsci Commodity Indexed Trust announced fiscal period ending Mar 31 2021 operating deficit of $-2.080345 millions

In the fiscal period ending Mar 31 2021 Ishares S And P Gsci Commodity Indexed Trust earnings per share more than doubled by 207.83 % of $1.51 per share compared to $0.49 a year ago and eps more than doubled by 259.52 % from $0.42 per share from the previous quarter.

Sales fell sharply by -87.77% to $0.14 millions from $1.17 millions in the same quarter a year ago and sequentially Sales fell by -29.76% from $0.20 millions.

Ames National Corporation

EPS Growth Accelerates Sharply

Ames National Corporation showed respectable growth in the first quarter of 2021 earnings season, where earnings jumped by 69.23 % year on year to $0.66 per share and Revenue increased by 24.21% to $16.60 millions.

Sequentially income per share increased by 18.18 % from $0.56 per share and Revenues advanced by 7.3 % from $15.47 millions.

Northwest Pipe Co

Northwest Pipe Co announced first quarter of 2021 operating surplus of $2.945 millions

Northwest Pipe Co posted very strong earnings results in the first quarter of 2021, where earnings per share more than doubled by 266.67 % at $0.22 per share, Sales grew modestly by 4.92% to $72.31 millions from the same quarter a year ago.

In the previous quarter company realized Sales of $69.38 millions and bottom line of $0.52 per share.

Cohu Inc

Turn into Profitability, Sales very Strong

Cohu Inc announced earnings per share of $0.61 and Sales of $150.65 millions in the financial time frame ending Mar 27 2021, Company's turn a round per share, versus $-0.42 eps, earned in the same quarter a year ago, although Cohu Inc saw its Sales rise by 58.78% in the same period.

In contrast to the third quarter Sales surged by 49.68 % from $150.65 millions and EPS turn positive from $-0.16 per share.

Verisk Analytics Inc

Verisk Analytics Inc announced first quarter of 2021 earnings season operating income of $250.4 millions

Verisk Analytics Inc delivered mixed results in the first quarter of 2021 earnings season, where Sales grew by 5.26% to $726.10 millions in comparison to $689.80 millions on a year-over-year basis, while earnings decreased by -0.96% to $1.03 per share, as comparison at $1.04 in the prior year quarter.

Sales increased by 1.79 % from $713.30 millions in preceding period, eps decreased by -3.71% from $1.07 per share.


Gilead Sciences Inc 's Segments
 Segment    3.14 % of total Revenue
 Segment    9.85 % of total Revenue
 Segment    4.26 % of total Revenue
HIV products Total
 Segment    24.47 % of total Revenue
 Segment    1.19 % of total Revenue
Other products
 Segment    2.56 % of total Revenue
 Segment    9.07 % of total Revenue
 Segment    2.04 % of total Revenue
 Segment    1.64 % of total Revenue
Complera Eviplera
 Segment    4.26 % of total Revenue
 Segment    5.18 % of total Revenue
 Segment    14.97 % of total Revenue
 Segment    41.84 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Gilead Sciences Inc does not provide revenue guidance.

Earnings Outlook
Verisk Analytics Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States 73.05 %
Other European countries 21.86 %
Other countries 5.09 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

AWRE's Profile

Stock Price

AWRE's Financials

Business Description


Charts & Quotes

AWRE's News


AWRE's Competitors

Customers & Markets

Economic Indicators

AWRE's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries





At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071